Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Analytical Method Development: SOP for Bioburden Method Development for APIs – V 2.0

Posted on By

Analytical Method Development: SOP for Bioburden Method Development for APIs – V 2.0

Standard Operating Procedure for Bioburden Testing Method Development for Active Pharmaceutical Ingredients (APIs)


Department Analytical Method Development
SOP No. SOP/AMD/225/2025
Supersedes SOP/AMD/225/2022
Page No. Page 1 of 13
Issue Date 21/05/2025
Effective Date 23/05/2025
Review Date 21/05/2026

1. Purpose

This SOP outlines the procedure for developing and validating bioburden testing methods for Active Pharmaceutical Ingredients (APIs), ensuring appropriate microbial enumeration and absence of specified organisms according to pharmacopeial

standards.

2. Scope

This SOP applies to non-sterile APIs and intermediates tested in the Analytical Method Development (AMD) department prior to formulation or downstream processing.

3. Responsibilities

  • Microbiologist: Develops and executes bioburden testing protocols, including media selection, dilution schemes, and recovery validation.
  • Analytical Scientist: Coordinates with microbiology to provide sample details and risk data.
  • QA Executive: Verifies results, approves protocols and ensures traceability.
See also  Analytical Method Development: SOP for NIR Method Development for In-Process Testing - V 2.0

4. Accountability

The Head of Analytical Method Development is accountable for ensuring validated and compliant bioburden methods are available for all APIs under analysis.

5. Procedure

5.1 Sample Preparation

  1. Weigh accurately 10 g (or prescribed quantity) of API under aseptic conditions.
  2. Transfer into sterile container with 90 mL of sterile diluent (e.g., 0.1% peptone water).
  3. Mix using vortex or shaker until the material is homogenized.
  4. Prepare decimal dilutions as required (e.g., 10-1, 10-2, 10-3).

5.2 Membrane Filtration or Plate Count

  1. Choose method based on sample solubility and microbial load:
    • Membrane filtration for insoluble APIs or low CFU samples.
    • Pour-plate/spread-plate for soluble APIs or expected high counts.
  2. Use TSA for Total Aerobic Microbial Count (TAMC) and SDA for Total Yeast and Mold Count (TYMC).
  3. Incubate:
    • TAMC: 30–35°C for 3–5 days
    • TYMC: 20–25°C for 5–7 days

5.3 Recovery Validation

  1. Spike API with known inoculum (~100 CFU) of challenge organisms (e.g., E. coli, S. aureus, C. albicans).
  2. Perform test as per method and calculate recovery:

    % Recovery = (CFU recovered / CFU inoculated) × 100
  3. Acceptable recovery: 70–130%
See also  Analytical Method Development: Interpretation of NMR Spectra in AMD - V 2.0

5.4 Method Suitability

  1. Test for microbial inhibition or enhancement by:
    • Comparing recovery from API sample vs. control (buffer only)
    • Neutralizing antimicrobial properties if present using lecithin/polysorbate 80

5.5 Specified Organisms (Optional)

  1. Test for presence/absence of:
    • Escherichia coli (Tryptic Soy Broth → MacConkey Agar)
    • Staphylococcus aureus (Soybean Casein Digest Broth → Mannitol Salt Agar)
    • Pseudomonas aeruginosa (Cetrimide Broth → Cetrimide Agar)
  2. Incubate and record growth; report as “Absent” if no colonies observed.

6. Abbreviations

  • SOP: Standard Operating Procedure
  • TAMC: Total Aerobic Microbial Count
  • TYMC: Total Yeast and Mold Count
  • CFU: Colony Forming Units
  • QA: Quality Assurance

7. Documents

  1. Bioburden Method Validation Worksheet – Annexure-1
  2. Recovery Validation Record – Annexure-2
  3. Specified Organism Detection Log – Annexure-3

8. References

  • USP <61> Microbiological Examination of Nonsterile Products: Microbial Enumeration Tests
  • USP <62> Tests for Specified Microorganisms
  • Ph. Eur. 2.6.12 and 2.6.13
  • ICH Q6A: Specifications

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name Santosh Borkar Neha Kapoor Sunita Reddy
Designation Microbiology Analyst QA Reviewer Head – AMD
Department Analytical Method Development QA Analytical Method Development

11. Annexures

Annexure-1: Bioburden Method Validation Worksheet

API Name Sample Weight Diluent Used Recovery Method Media
Metformin HCl 10 g 0.1% Peptone Water Membrane Filtration TSA/SDA

Annexure-2: Recovery Validation Record

Organism CFU Inoculated CFU Recovered Recovery (%) Status
C. albicans 98 95 96.9% Pass

Annexure-3: Specified Organism Detection Log

Organism Media Used Result Status
E. coli MacConkey Agar No Growth Absent

Revision History:

Revision Date Revision No. Details Reason Approved By
21/05/2025 2.0 Expanded to include recovery validation and specified organism detection Annual Review and Audit Findings Sunita Reddy
15/05/2022 1.0 Initial SOP Release New SOP QA Head
See also  Analytical Method Development: SOP for pH Determination of Semi-Solid Formulations - V 2.0
Analytical Method Development V 2.0 Tags:Analytical Method Development SOP, SOP for analytical calculations, SOP for analytical documentation, SOP for analytical instrument calibration, SOP for analytical instrument qualification, SOP for analytical method change control, SOP for analytical method deviation handling, SOP for analytical method documentation practices, SOP for analytical method lifecycle management, SOP for analytical method optimization, SOP for analytical method risk assessment, SOP for analytical method training and competency, SOP for analytical method transfer protocol, SOP for analytical method validation, SOP for forced degradation studies, SOP for HPLC method development, SOP for limit of detection (LOD) determination, SOP for limit of quantitation (LOQ) determination, SOP for method accuracy testing, SOP for method linearity assessment, SOP for method precision evaluation, SOP for method reproducibility, SOP for method robustness testing, SOP for method transfer, SOP for method verification, SOP for qualification of working standards, SOP for reference standard handling, SOP for specificity testing in analytical methods, SOP for stability indicating methods, SOP for system suitability testing

Post navigation

Previous Post: No Policy for Electronic Signatures: A Data Integrity Red Flag in GMP Systems
Next Post: Auditable vs Non-Auditable SOP Content: What to Include and Avoid

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version